Feature | Tweets: They're Educational
Thanks to our many tweeters at ACC.19 – Pathway, Early Career and FIT – for extending the reach of all the learning available at ACC.19.
Check out these top tweets and for more of what you may have missed check out #ACC19.
Try out https://t.co/1u7fOup51L if you haven't already. Great way to network with #cvteam #ACCCVManage #ACC19 @TNChapterACC @ACCinTouch https://t.co/RmxkpIIi72— Alison L. Bailey, MD (@a_l_bailey) March 16, 2019
#AppleHeartStudy questions that remain:— JK Han MD (@netta_doc) March 16, 2019
🔺What will our older patient cohort think / allow / do with his technology?
🔺What will the cost-effectiveness be?
🔺How will this impact general cardiologists & #EPeeps AKA...
🔺What is the signal:noise ratio?#ACC19 #ACCEP @ACCinTouch pic.twitter.com/XQyV78rhzo
#Telemedicine leads to better provider & #PatientExperience in routine care. Time to align with the #DigitalHealth research revolution. Let's not run in parallel anymore! @ACCinTouch @MGHHeartHealth @arwmd @iamritu @AmericanTelemed #ClinicianWellBeing #ACC19 #CHD #ACCHI pic.twitter.com/3gmj0mVI7p— Ami Bhatt (@AmiBhattMD) March 16, 2019
We need to start initiating sacubitril/valsartan in inpatients. Inpatient admission is a great opportunity to initiate and optimize GDMT to improve adherence #ACC19 #HeartFailure cc: @gcfmd https://t.co/3ELefechMy— Nasrien E. Ibrahim, MD (@IAmDrIbrahim) March 16, 2019
Aggressive guideline directed treatment of risk factors matters for #SIHD - Let's not forgot - Greater risk factor control showed incrementally greater survival #ACCIC #ACC19 #COURAGE pic.twitter.com/iDPwZdj7fL— Dr. Sheila Sahni (@DrSheilaSahni) March 16, 2019
Machine Learning : How can it be applied for diagnosing ischemia— Dr. Purvi Parwani (@purviparwani) March 16, 2019
Great talk by Dr.Jim Min#ACCImaging #ACC19 #CVImaging pic.twitter.com/13p9uRzmPx
Packed room for 2018 Cholesterol guidelines at #ACC19 @ACCinTouch #cvPrev in Room 228. @braun_lynne @nstonedoc @dmljmd pic.twitter.com/k1T3WQ1Xen— AnnabelleVolgman MD (@avolgman) March 16, 2019
Nice table of considerations while choosing an anticoagulant in patients with cancer by @AArmbruster09 @ACCinTouch #cvVTE #cvPH pic.twitter.com/mZRpaCyyKr— Tina Shah (@TinaShahMD) March 16, 2019
Platelet count pre #TAVR seems to be an issue just like post-TAVR. But have to question the why- what conditions lead to low plt? And what do we do about it? #ACC19 @ACCinTouch #cvVHD @MDMankad @michelenahector @purviparwani @MayoClinicCV pic.twitter.com/RKdM2B8Xqr— Rekha Mankad, MD (@RMankadMD) March 16, 2019
And we're off! @AnishBadjatiya from @DukeHeartCenter— Alec Schmaier (@ASchmaier) March 16, 2019
Presents on PAD demographics and outcomes in the the EXSCEL trial of exenatide in diabetes and CV outcomes. Come by the moderated poster session #acc19 #vasculardisease pic.twitter.com/PNLt3pdwvC
Keywords: ACC Publications, Cardiology Magazine, ACC Annual Scientific Session, ACC19, Algorithms, Anxiety, Aspirin, Anticoagulants, Cardiovascular Diseases, Atrial Fibrillation, Comorbidity, Control Groups, Depression, Electrocardiography, Ambulatory, Dementia, Drug-Eluting Stents, Intention to Treat Analysis, Heart Failure, Malus, Mitral Valve, Mitral Valve Insufficiency, Myocardial Infarction, National Heart, Lung, and Blood Institute (U.S.), Odds Ratio, Patient Selection, Patient Readmission, Photoplethysmography, Precipitating Factors, Pyrazoles, Quality of Life, Psychiatry, Pyridones, Risk Factors, Referral and Consultation, Venous Thromboembolism, Self Report, Substance-Related Disorders, Research Personnel, Ticlopidine, Ventricular Dysfunction, Right, Stroke, Warfarin
< Back to Listings